Astellas Pharma (4503) Stock Overview
Manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
4503 Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Astellas Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,624.50 |
| 52 Week High | JP¥1,810.50 |
| 52 Week Low | JP¥1,243.50 |
| Beta | 0.10 |
| 1 Month Change | -2.37% |
| 3 Month Change | 15.87% |
| 1 Year Change | -5.99% |
| 3 Year Change | -17.45% |
| 5 Year Change | 8.26% |
| Change since IPO | 176.28% |
Recent News & Updates
Recent updates
Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's
Sep 19
Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 01Astellas Pharma (TSE:4503) Is Increasing Its Dividend To ¥39.00
Jul 24Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year
Jul 10Astellas Pharma Inc.'s (TSE:4503) P/E Is On The Mark
Jun 20Statutory Profit Doesn't Reflect How Good Astellas Pharma's (TSE:4503) Earnings Are
May 08Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Apr 29These 4 Measures Indicate That Astellas Pharma (TSE:4503) Is Using Debt Reasonably Well
Mar 13Astellas Pharma (TSE:4503) Is Due To Pay A Dividend Of ¥37.00
Feb 15Astellas Pharma Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now
Feb 07Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00
Feb 01Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00
Jan 17Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00
Jan 03
Strategic Brands XTANDI And PADCEV Ignite Growth And Boost Margins In Pharma Innovator
Strategic brand growth and expanded product indications are driving revenue and upward revisions in forecasts, particularly in key markets like the U.S.Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥37.00
Dec 04Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point
Nov 06Astellas Pharma Inc. (TSE:4503) Just Released Its Half-Yearly Earnings: Here's What Analysts Think
Nov 01Astellas Pharma Inc.'s (TSE:4503) Earnings Haven't Escaped The Attention Of Investors
Oct 15Shareholder Returns
| 4503 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -1.2% | 3.9% | -1.8% |
| 1Y | -6.0% | -5.3% | 15.3% |
Return vs Industry: 4503 matched the JP Pharmaceuticals industry which returned -5.7% over the past year.
Return vs Market: 4503 underperformed the JP Market which returned 14.2% over the past year.
Price Volatility
| 4503 volatility | |
|---|---|
| 4503 Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in JP Market | 7.7% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4503 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4503's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 13,643 | Naoki Okamura | www.astellas.com |
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD); EVRENZO, a treatment for anemia associated with chronic kidney disease (CKD); Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressants.
Astellas Pharma Inc. Fundamentals Summary
| 4503 fundamental statistics | |
|---|---|
| Market cap | JP¥2.91t |
| Earnings (TTM) | JP¥81.57b |
| Revenue (TTM) | JP¥1.94t |
Is 4503 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4503 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.94t |
| Cost of Revenue | JP¥352.90b |
| Gross Profit | JP¥1.59t |
| Other Expenses | JP¥1.51t |
| Earnings | JP¥81.57b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 45.56 |
| Gross Margin | 81.86% |
| Net Profit Margin | 4.19% |
| Debt/Equity Ratio | 60.0% |
How did 4503 perform over the long term?
See historical performance and comparisonDividends
Does 4503 pay a reliable dividends?
See 4503 dividend history and benchmarks| Astellas Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Sep 29 2025 |
| Dividend Pay Date | Dec 02 2025 |
| Days until Ex dividend | 6 days |
| Days until Dividend pay date | 58 days |
Does 4503 pay a reliable dividends?
See 4503 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 14:16 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Astellas Pharma Inc. is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hazim Bahari | CFRA Equity Research |